Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
196.31
+4.92 (2.57%)
Feb 26, 2026, 3:14 PM EST - Market open
Ligand Pharmaceuticals Market Cap
Ligand Pharmaceuticals has a market cap or net worth of $3.86 billion as of February 26, 2026. Its market cap has increased by 79.18% in one year.
Market Cap
3.86B
Enterprise Value
3.66B
1-Year Change
79.18%
Ranking
Category
Stock Price
$196.31
Market Cap Chart
Since December 1, 1998, Ligand Pharmaceuticals's market cap has increased from $430.80M to $3.86B, an increase of 796.87%. That is a compound annual growth rate of 8.38%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 3.77B | 1.23% |
| Dec 31, 2025 | 3.72B | 83.80% |
| Dec 31, 2024 | 2.02B | 62.58% |
| Dec 29, 2023 | 1.25B | 10.35% |
| Dec 30, 2022 | 1.13B | -56.28% |
| Dec 31, 2021 | 2.58B | 61.30% |
| Dec 31, 2020 | 1.60B | -12.63% |
| Dec 31, 2019 | 1.83B | -36.49% |
| Dec 31, 2018 | 2.88B | -0.20% |
| Dec 29, 2017 | 2.89B | 36.08% |
| Dec 30, 2016 | 2.12B | -1.70% |
| Dec 31, 2015 | 2.16B | 102.78% |
| Dec 31, 2014 | 1.07B | -0.76% |
| Dec 31, 2013 | 1.07B | 159.26% |
| Dec 31, 2012 | 414.10M | 77.34% |
| Dec 30, 2011 | 233.50M | 33.50% |
| Dec 31, 2010 | 174.90M | -28.67% |
| Dec 31, 2009 | 245.20M | -5.73% |
| Dec 31, 2008 | 260.10M | -43.57% |
| Dec 31, 2007 | 460.90M | -46.88% |
| Dec 29, 2006 | 867.60M | 4.96% |
| Dec 30, 2005 | 826.60M | -3.95% |
| Dec 31, 2004 | 860.60M | -19.85% |
| Dec 31, 2003 | 1.07B | 179.68% |
| Dec 31, 2002 | 383.90M | -64.11% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Erasca | 4.17B |
| NewAmsterdam Pharma Company | 4.03B |
| Centessa Pharmaceuticals | 3.94B |
| Corcept Therapeutics | 3.85B |
| Viking Therapeutics | 3.83B |
| ADMA Biologics | 3.73B |
| Alumis | 3.66B |
| Legend Biotech | 3.64B |